Tramadol precautions: Difference between revisions
No edit summary |
m Reverted edits by Puwok2008bD8O (talk) to last revision by NNethala |
||
| Line 21: | Line 21: | ||
<br> | <br> | ||
===General=== | ===General=== | ||
The recommended dose of | The recommended dose of Tramadol should not be exceeded. | ||
Do not co-administer | Do not co-administer Tramadol with other tramadol or acetaminophen-containing products. ''[[Tramadol precautions#List of precautions|Return to top]]'' | ||
<br> | <br> | ||
===Pediatric Use=== | ===Pediatric Use=== | ||
The safety and effectiveness of | The safety and effectiveness of Tramadol has not been studied in the pediatric population. | ||
<br> | <br> | ||
===Geriatric Use=== | ===Geriatric Use=== | ||
| Line 31: | Line 31: | ||
<br> | <br> | ||
===Acute Abdominal Conditions=== | ===Acute Abdominal Conditions=== | ||
The administration of | The administration of Tramadol may complicate the clinical assessment of patients with acute | ||
abdominal conditions. ''[[Tramadol precautions#List of precautions|Return to top]]'' | abdominal conditions. ''[[Tramadol precautions#List of precautions|Return to top]]'' | ||
<br> | <br> | ||
===Use in Renal Disease=== | ===Use in Renal Disease=== | ||
Tramadol has not been studied in patients with impaired renal function. Experience with tramadol | |||
suggest that impaired renal function results in a decreased rate and extent of excretion of tramadol and its active metabolite, M1. In patients with creatinine clearances of less than 30 mL/min, it is | suggest that impaired renal function results in a decreased rate and extent of excretion of tramadol and its active metabolite, M1. In patients with creatinine clearances of less than 30 mL/min, it is | ||
recommended that the dosing interval of | recommended that the dosing interval of Tramadol be increased not to exceed 2 tablets every 12 | ||
hours. ''[[Tramadol precautions#List of precautions|Return to top]]'' | hours. ''[[Tramadol precautions#List of precautions|Return to top]]'' | ||
<br> | <br> | ||
===Use in Hepatic Disease=== | ===Use in Hepatic Disease=== | ||
Tramadol has not been studied in patients with impaired hepatic function. The use of Tramadol in | |||
patients with hepatic impairment is not recommended. ''[[Tramadol precautions#List of precautions|Return to top]]'' | patients with hepatic impairment is not recommended. ''[[Tramadol precautions#List of precautions|Return to top]]'' | ||
<br> | <br> | ||
Latest revision as of 15:39, 18 December 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
List of precautions
General
Pediatric Use
Geriatric Use
Acute Abdominal Conditions
Use in Renal Disease
Use in Hepatic Disease
General
The recommended dose of Tramadol should not be exceeded.
Do not co-administer Tramadol with other tramadol or acetaminophen-containing products. Return to top
Pediatric Use
The safety and effectiveness of Tramadol has not been studied in the pediatric population.
Geriatric Use
In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function; of concomitant disease and multiple drug therapy. Return to top
Acute Abdominal Conditions
The administration of Tramadol may complicate the clinical assessment of patients with acute
abdominal conditions. Return to top
Use in Renal Disease
Tramadol has not been studied in patients with impaired renal function. Experience with tramadol
suggest that impaired renal function results in a decreased rate and extent of excretion of tramadol and its active metabolite, M1. In patients with creatinine clearances of less than 30 mL/min, it is
recommended that the dosing interval of Tramadol be increased not to exceed 2 tablets every 12
hours. Return to top
Use in Hepatic Disease
Tramadol has not been studied in patients with impaired hepatic function. The use of Tramadol in
patients with hepatic impairment is not recommended. Return to top
Adapted from the FDA Package Insert.